List your tool

Head to head · 2026

Tempus AI vs Zephyr AI

Pricing, free plans, ratings, features, pros and cons, side by side. Where one comes out ahead, we mark it.

Tempus AI

Publicly traded on Nasdaq, guiding to $1.6 billion in 2026 revenue

4.3Not listed

Visit Tempus AI (opens Tempus AI in a new tab)

Zephyr AI

Precision medicine from real-world data, with interpretable models and no new assays

4.0Not listed

Visit Zephyr AI (opens Zephyr AI in a new tab)

Who comes out ahead

Based only on the facts in our directory. The right pick still depends on the job you need done.

  • Lower starting price

    Not comparable

    Not comparable: Tempus AI does not list a price

  • Free plan

    Tie

    Neither has one

  • Higher rating

    Tempus AI

    4.3 against 4.0

  • Same job?

    Yes

    Both are Healthcare AI tools

Side by side

Compared onTempus AIZephyr AI
Our rating4.3Better4.0
Starts atNot listedNot listed
Free planNoNo
CategoryHealthcare AIHealthcare AI
PlansSee pricingSee pricing
Key features
  • Machine learning applied to genomic and clinical data for precision treatment matching
  • One of the largest connected libraries of clinical and molecular data
  • Publicly traded on Nasdaq under the ticker TEM
  • Q1 2026 revenue of $348.1M, up 36.1% year over year
  • 2026 revenue guidance raised to $1.59-$1.60 billion
  • Multi-modal real-world data integration
  • Interpretable machine learning models
  • Discovery, validation and deployment coverage
  • Enterprise-scale data processing
  • Fits existing workflows with no new assays required
Pros
  • Publicly reported financials give unusual transparency into scale and growth
  • Massive, growing data library strengthens precision-matching over time
  • Strong, consistent revenue growth across both diagnostics and data segments
  • Interpretable models, which is what makes a target hypothesis actionable
  • Works on data already generated rather than requiring new collection
  • Covers the therapeutic lifecycle rather than one stage
Cons
  • Pricing runs through insurance billing and enterprise agreements, not published rates
  • Built specifically for precision medicine and oncology, a narrower clinical scope
  • Best suited to institutions already positioned to act on genomic testing results
  • No published pricing, contact only
  • Real-world data carries the biases of who received care and where
  • Findings need prospective validation before changing clinical decisions
CompanyTempus AI, founded 2015Zephyr AI

Prices come from each vendor's pricing page, last checked 20260814. Check the vendor before you buy.

FAQ

Questions people ask

Is Tempus AI better than Zephyr AI?

In our reviews Tempus AI scores 4.3 and Zephyr AI scores 4.0. The better pick depends on the job. Tempus AI: Publicly traded on Nasdaq, guiding to $1.6 billion in 2026 revenue. Zephyr AI: Precision medicine from real-world data, with interpretable models and no new assays.

Which is cheaper, Tempus AI or Zephyr AI?

Tempus AI: see pricing. Zephyr AI: see pricing.

Do Tempus AI and Zephyr AI have free plans?

Neither lists a free plan.

More comparisons